Soleno Therapeutics (SLNO) News Today $46.88 +0.89 (+1.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Soleno Therapeutics (NASDAQ:SLNO) Trading 8.6% Higher - Here's What HappenedSoleno Therapeutics (NASDAQ:SLNO) Stock Price Up 8.6% - Here's WhyJanuary 15, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by BrokeragesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) has received a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigneJanuary 15, 2025 | marketbeat.comIs Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?January 13, 2025 | insidermonkey.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,340 Shares of StockJanuary 7, 2025 | insidertrades.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $108,061.20 in StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 2,340 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total value of $108,061.20. Following the completion of the transaction, the insider now directly owns 76,605 shares in the company, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 6, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) CFO Sells 4,083 Shares of StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CFO James H. Mackaness sold 4,083 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $185,409.03. Following the completion of the sale, the chief financial officer now owns 115,089 shares of the company's stock, valued at $5,226,191.49. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.January 6, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Sells 10,937 Shares of StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total value of $496,649.17. Following the completion of the transaction, the chief executive officer now owns 708,616 shares in the company, valued at approximately $32,178,252.56. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.January 6, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Shares Down 2.5% - Here's WhySoleno Therapeutics (NASDAQ:SLNO) Shares Down 2.5% - Should You Sell?January 6, 2025 | marketbeat.comStock Traders Buy High Volume of Put Options on Soleno Therapeutics (NASDAQ:SLNO)Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors purchased 11,493 put options on the stock. This represents an increase of 451% compared to the typical daily volume of 2,084 put options.December 30, 2024 | marketbeat.comGeode Capital Management LLC Buys 51,189 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Geode Capital Management LLC raised its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 10.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 540,296 shares of the company's stock after purchasingDecember 27, 2024 | marketbeat.comBarclays PLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Barclays PLC increased its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 149.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,545 shares of the company'December 25, 2024 | marketbeat.com13,001 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Teachers Retirement System of The State of KentuckyTeachers Retirement System of The State of Kentucky purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 13,001 shares of the company's stock, valued at approximately $656,000. SDecember 19, 2024 | marketbeat.comState Street Corp Has $57.67 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)State Street Corp boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 14.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,142,169 shares of the company's stock aDecember 19, 2024 | marketbeat.comSoleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLCDecember 17, 2024 | globenewswire.comSoleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For MeDecember 14, 2024 | seekingalpha.comWellington Management Group LLP Purchases 290,135 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Wellington Management Group LLP lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 73.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 683,170 shares of the cDecember 13, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 208.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 192,597 shares of the company's stocDecember 10, 2024 | marketbeat.comFmr LLC Raises Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Fmr LLC grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6,048,754.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 665,374 shares of the company's stock after buying an additional 665,363 shares during the quarter. Fmr LLC owned 1.54December 9, 2024 | marketbeat.comPolar Asset Management Partners Inc. Sells 42,900 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Polar Asset Management Partners Inc. reduced its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 57.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,600 shares of the company's stock after seDecember 6, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for SLNO FY2024 Earnings?Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Soleno Therapeutics in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now expects that thDecember 4, 2024 | marketbeat.comJanus Henderson Group PLC Has $206.02 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Janus Henderson Group PLC raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 21.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,081,099 shares of the company's stock after purchasing an addDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Buys New Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)HighVista Strategies LLC bought a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,085 shares of the company's stock,December 4, 2024 | marketbeat.comHolocene Advisors LP Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Holocene Advisors LP raised its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 10.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 594,364 shares of the company's stock after purDecember 3, 2024 | marketbeat.comConfident Buy Rating on Soleno Therapeutics Amidst Imminent FDA Approval and Strong ValuationDecember 3, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Soleno Therapeutics (SLNO)December 3, 2024 | markets.businessinsider.comMartingale Asset Management L P Takes $1.11 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Martingale Asset Management L P purchased a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 21,975 shares of the company's stock, valuDecember 2, 2024 | marketbeat.comShort Interest in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Drops By 23.2%Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 4,740,000 shares, a drop of 23.2% from the October 31st total of 6,170,000 shares. Approximately 14.8% of the company's stock are short sold. Based on an average daily trading volume, of 654,000 shares, the days-to-cover ratio is presently 7.2 days.November 29, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Vestal Point Capital LPVestal Point Capital LP cut its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 40.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 720,000 shares of the company's stock after selliNovember 29, 2024 | marketbeat.comWhat the Options Market Tells Us About Soleno TherapeuticsNovember 27, 2024 | benzinga.comSoleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comSoleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatmentNovember 26, 2024 | seekingalpha.comSoleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeNovember 26, 2024 | globenewswire.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of "Buy" by BrokeragesShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have earned a consensus rating of "Buy" from the seven research firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a stNovember 26, 2024 | marketbeat.comWestfield Capital Management Co. LP Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Westfield Capital Management Co. LP purchased a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 495,708 shares of the company's stocNovember 25, 2024 | marketbeat.comSoleno Therapeutics Reports Q3 Progress and FinancialsNovember 21, 2024 | markets.businessinsider.comSoleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024November 14, 2024 | globenewswire.comHere's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn SituationNovember 12, 2024 | finance.yahoo.comSoleno Therapeutics (NASDAQ:SLNO) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research note on Monday.November 11, 2024 | marketbeat.comPositive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash PositionNovember 9, 2024 | markets.businessinsider.comCantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)November 8, 2024 | markets.businessinsider.comSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | finance.yahoo.comHarbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Harbor Capital Advisors Inc. purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 36,048 shares of the company's stock, valued at approximately $1,82November 6, 2024 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Stock, Option ChainNovember 3, 2024 | benzinga.comEmerald Advisers LLC Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Emerald Advisers LLC raised its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 313,334 shares of the company's stock after buying an additioNovember 3, 2024 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Recommendation of "Buy" by AnalystsShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy raNovember 1, 2024 | marketbeat.comSoleno Therapeutics price target raised to $73 from $65 at OppenheimerOctober 29, 2024 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High on Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year High on Analyst UpgradeOctober 28, 2024 | marketbeat.comSoleno Therapeutics to Participate in Upcoming November Investor ConferencesOctober 28, 2024 | tmcnet.comSoleno Therapeutics announces passing of former chairman Ernest MarioOctober 22, 2024 | markets.businessinsider.comSoleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.October 21, 2024 | markets.businessinsider.com Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Media Mentions By Week SLNO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLNO News Sentiment▼1.040.44▲Average Medical News Sentiment SLNO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLNO Articles This Week▼34▲SLNO Articles Average Week Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bausch + Lomb News Inspire Medical Systems News Inari Medical News PROCEPT BioRobotics News Envista News iRhythm Technologies News NovoCure News LivaNova News Enovis News Warby Parker News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLNO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
